Instrument Inactif

Gouvernance Five Prime Therapeutics, Inc.

FPRX

US33830X1046

Recherche biotechnologique et médicale

Comité Exécutif: Five Prime Therapeutics, Inc.

Dirigeant

Fonctions occupéesDepuis

James Bradner

53 ans

Chief Executive Officer

Jonathan Graham

65 ans

Corporate Secretary

Peter Griffith

67 ans

Director of Finance/CFO

Composition du Conseil d'Administration: Five Prime Therapeutics, Inc.

Administrateur	ComitésDepuis

Anciens Dirigeants et Administrateurs: Five Prime Therapeutics, Inc.

Insider

Fonctions occupées

DepuisJusqu'au

Francis Sarena

General Counsel	01/12/2010	01/09/2016
Corporate Officer/Principal	01/09/2016	16/05/2021
Corporate Secretary	01/12/2010	01/09/2016

William Ringo

Director/Board Member	01/10/2014	01/01/2019
Chief Executive Officer	19/09/2019	13/04/2020
Chairman	01/01/2019	16/04/2021
Independent Dir/Board Member	01/10/2014	16/04/2021

Franklin Berger

Director/Board Member	27/09/2010	16/04/2021
Independent Dir/Board Member	27/09/2010	16/04/2021

Thomas Civik

Director/Board Member	13/04/2020	16/04/2021
Chief Executive Officer	13/04/2020	16/04/2021
President	13/04/2020	16/04/2021

Nallakkan S. Arvindan

Corporate Officer/Principal

01/02/2018

16/04/2021

Lori Lyons-Williams

Director/Board Member	23/06/2019	16/04/2021
Independent Dir/Board Member	23/06/2019	16/04/2021

Carol Schafer

Director/Board Member	15/05/2019	16/04/2021
Independent Dir/Board Member	15/05/2019	16/04/2021

Martin Forrest

Investor Relations Contact	01/01/2019	16/04/2021
Public Communications Contact	01/01/2019	16/04/2021

David White

Comptroller/Controller/Auditor	28/02/2019	16/04/2021
Corporate Officer/Principal	25/02/2019	28/02/2019

David Smith

Director of Finance/CFO

26/11/2018

16/04/2021

Garry Nicholson

Director/Board Member	10/05/2017	16/04/2021
Independent Dir/Board Member	10/05/2017	16/04/2021

Helen Collins

Chief Tech/Sci/R&D Officer

20/03/2017

16/04/2021

Kapil Dhingra

Director/Board Member	03/12/2015	16/04/2021
Independent Dir/Board Member	03/12/2015	16/04/2021

Peder Jensen

Director/Board Member	01/07/2011	16/04/2021
Independent Dir/Board Member	01/07/2011	16/04/2021

Melissa Abel

Corporate Officer/Principal

01/01/2016

01/01/2020

Lewis Williams

Director/Board Member	01/01/2019	31/12/2019
Chief Executive Officer	01/08/2011	02/01/2018
Chairman	15/03/2016	01/01/2019
Founder	01/12/2001	31/12/2019
President	16/09/2011	02/01/2018

Aron M. Knickerbocker

Director/Board Member	17/10/2013	19/09/2019
Chief Executive Officer	01/01/2018	19/09/2019
Chief Operating Officer	08/09/2016	01/01/2018
Investor Relations Contact	01/09/2009	-
Corporate Officer/Principal	01/09/2009	-
President	01/01/2018	19/09/2019

Sheila Gujrathi

Director/Board Member	03/12/2015	07/06/2019
Independent Dir/Board Member	-	07/06/2019

Bryan Irving

Chief Tech/Sci/R&D Officer

01/08/2017

30/05/2019

Luis Borges

Director/Board Member	01/02/2015	01/06/2015
Chief Tech/Sci/R&D Officer	01/05/2014	01/03/2019
Corporate Officer/Principal	01/05/2014	01/01/2015

Jeff P. Coon

Human Resources Officer

01/04/2017

01/01/2019

Mark McDade

Director/Board Member	07/08/2006	30/11/2018
Independent Dir/Board Member	01/07/2006	30/11/2018

Linda Rubinstein

Comptroller/Controller/Auditor	13/04/2018	26/11/2018
Director of Finance/CFO	13/04/2018	26/11/2018

Fred Cohen

Director/Board Member	01/05/2002	10/05/2018
Independent Dir/Board Member	01/05/2002	10/05/2018

Marc Belsky

Director of Finance/CFO

21/01/2010

06/04/2018

R. Lee Douglas

Director/Board Member	01/01/2002	10/05/2017
Founder	01/01/2002	10/05/2017
Independent Dir/Board Member	01/01/2002	10/05/2017

Robert Steven Sikorski

Chief Tech/Sci/R&D Officer	01/06/2016	20/03/2017
Corporate Officer/Principal	20/03/2017	30/04/2017

Brian Atwood

Chairman	01/05/2002	15/03/2016
Independent Dir/Board Member	01/05/2002	15/03/2016

Julie Hambleton

Chief Tech/Sci/R&D Officer

03/12/2012

15/02/2016

Brian Wong

Chief Tech/Sci/R&D Officer	27/04/2015	30/08/2015
Corporate Officer/Principal	01/01/2009	27/04/2015

Kevin P. Baker

Corporate Officer/Principal	01/01/2006	01/07/2015
Corporate Officer/Principal	01/02/2016	01/06/2018

William Michael Kavanaugh

Chief Tech/Sci/R&D Officer

21/01/2010

01/12/2014

Calvin Yu

Comptroller/Controller/Auditor

01/03/2010

01/09/2014

Anna L. Barry

Corporate Officer/Principal

01/01/2011

01/01/2014

Brook Byers

Director/Board Member

Min MIn Qin

Director/Board Member

01/01/2005

01/08/2012

Julia Gregory

Director/Board Member	01/01/2009	01/08/2011
Chief Executive Officer	01/01/2009	01/08/2011
President	01/01/2009	01/08/2011

Jeffrey Finer

Private Equity Investor

01/01/2007

02/08/2011

Deborah Charych

Corporate Officer/Principal

01/01/2007

01/01/2010

Lauretta Cesario

Human Resources Officer

21/01/2010

Gail Maderis

Chief Executive Officer	01/01/2003	01/01/2009
President	01/01/2003	01/01/2009

Stephen Doberstein

Chief Tech/Sci/R&D Officer

01/07/2004

01/10/2008

Lorianne Masuoka

Corporate Officer/Principal

01/01/2003

01/08/2008

James Blair

Director/Board Member

Harold Keer

Chief Tech/Sci/R&D Officer	06/07/2011	-
Corporate Officer/Principal	-	06/07/2011

Amy L. Tsui Collins

General Counsel	21/01/2010	-
Corporate Officer/Principal	-	21/01/2010

Rowe Heather Armstrong

Investor Relations Contact	-	-
Public Communications Contact	-	-

Buckley Kohlhauff

Chief Tech/Sci/R&D Officer

Drew Pardoll

Consultant / Advisor

Jean George

Director/Board Member

David Reese

Chief Executive Officer

Amy Kendall

Public Communications Contact

Dan Iazzetti

Human Resources Officer

Usha Arunachalam

Corporate Officer/Principal

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	3
Femme	0

Dont comité exécutif

Homme	3
Femme	0

Dont Administrateurs

Homme	0
Femme	0

Five Prime Therapeutics, Inc. est une société de biotechnologie au stade clinique qui se concentre sur la découverte et le développement de protéines thérapeutiques. La Société se concentre principalement sur la recherche et le développement d'immuno-oncologie et de thérapies ciblées contre le cancer. Le portefeuille de produits de la Société comprend le bemarituzumab (FPA144), un anticorps qui inhibe le récepteur 2b du facteur de croissance des fibroblastes, ou FGFR2b, qu'elle étudie dans un essai clinique en association avec le 5-fluorouracile (5-FU), la leucovorine et l'oxaliplatine ; le FPA150, un anticorps inhibiteur du point de contrôle des lymphocytes T CD8 qui cible B7-H4 ; FPT155, qui est une protéine de fusion CD80 soluble qui améliore la co-stimulation des cellules T par CD28 ; Cabiralizumab (FPA008), qui est un anticorps qui inhibe le récepteur du facteur-1 stimulant les colonies, qu'il étudie dans des essais cliniques, et BMS-986258, qui est un anticorps anti-domaine 3 de l'immunoglobuline et de la mucine des cellules T, ou TIM-3.

Employés

Secteur

Recherche biotechnologique et médicale

Plus d'informations sur la société